Pfizer and German mRNA biotech partner BioNTech have released an early look at their experimental pandemic vaccine, and the news is good. The pair’s mRNA-based vaccine candidate, BNT162b2, has shown in its closely watched phase 3 that it was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Source: Fierce Biotech 9/11/2020